Skip to Main Content

WASHINGTON — The Food and Drug Administration will have to explain to a court this week why it won’t shed more light on an internal decision to allow at least two Americans who contracted Ebola to take a drug that wasn’t yet approved.

It’s the latest salvo in a legal case that could have broader implications for the ongoing campaign to pass a federal “right-to-try” law, in which advocates are aiming to help dying patients get access to other drugs the FDA hasn’t yet approved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!